drugset / Trial / NCT04586985
Safety, Tolerability and Pharmacokinetics of FTX-6058
RandomizedSequentialQuadruple-blindTreatment
Summary
This is a study to evaluate the safety, tolerability and pharmacokinetics of FTX-6058 in healthy adult subjects and adult subjects with sickle cell disease (SCD).
Timeline
- Start
- 2020-10-26
- Primary completion
- 2022-11-15
- Completion
- 2022-11-15
Outcome
Met primary endpoint
release “the interim results from this clinical trial of FTX-6058, which demonstrated compelling results across all primary, secondary, and exploratory endpoints included in this study.” fulcrumtx.com ↗
Publications
- Background Ngo DA, Aygun B, Akinsheye I, Hankins JS, Bhan I, Luo HY, Steinberg MH, Chui DH. Fetal haemoglobin levels and haematological characteristics of compound heterozygotes for haemoglobin S and deletional hereditary persistence of fetal haemoglobin. Br J Haematol. 2012 Jan;156(2):259-64. doi: 10.1111/j.1365-2141.2011.08916.x. Epub 2011 Oct 24.
- Background Piel FB, Steinberg MH, Rees DC. Sickle Cell Disease. N Engl J Med. 2017 Apr 20;376(16):1561-1573. doi: 10.1056/NEJMra1510865. No abstract available.
- Background Sankaran VG, Orkin SH. The switch from fetal to adult hemoglobin. Cold Spring Harb Perspect Med. 2013 Jan 1;3(1):a011643. doi: 10.1101/cshperspect.a011643.
- Background Saraf SL, Molokie RE, Nouraie M, Sable CA, Luchtman-Jones L, Ensing GJ, Campbell AD, Rana SR, Niu XM, Machado RF, Gladwin MT, Gordeuk VR. Differences in the clinical and genotypic presentation of sickle cell disease around the world. Paediatr Respir Rev. 2014 Mar;15(1):4-12. doi: 10.1016/j.prrv.2013.11.003. Epub 2013 Nov 15.
- Background Steinberg MH, Chui DH, Dover GJ, Sebastiani P, Alsultan A. Fetal hemoglobin in sickle cell anemia: a glass half full? Blood. 2014 Jan 23;123(4):481-5. doi: 10.1182/blood-2013-09-528067. Epub 2013 Nov 12.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Midazolam | Small molecule | 3 mg | Oral |
| Subject | Pociredir | Small molecule | 2 mg | Oral |
| Subject | Pociredir | Small molecule | 4 mg | Oral |
| Subject | Pociredir | Small molecule | 6 mg | Oral |
| Subject | Pociredir | Small molecule | 10 mg | Oral |
| Subject | Pociredir | Small molecule | 20 mg | Oral |
| Subject | Pociredir | Small molecule | 30 mg | Oral |
| Subject | Pociredir | Small molecule | 40 mg | Oral |
| Subject | Pociredir | Small molecule | 60 mg | Oral |
| Subject | Pociredir | Small molecule | 90 mg | Oral |